稳步获得批准：2025年主要潜在药物上市

Key Potential Drug Launches in 2025 According to Biomedtracker’s Key Potential Drug Launches in 2025 report, the pipeline isset to deliver 69 key launches across 66 discrete drugs next year.* This is roughly the samenumber as predicted for 2024 back in July 2023.*Data as of July 2024 Just over half of the key launches forecast for 2025 havethe potential to change disease treatment practices. These include LIB Therapeutics’ lerodalcibep, an injectablerecombinant fusion protein that could transform treatmentfor dyslipidemia and hypercholesterolemia; and CagriSema,another game-changing obesity treatment from NovoNordisk. Source: Biomedtracker, July 2024 Key potential drug launches in 2025 by therapeutic area Oncology remains the leading therapeutic category in terms of key potential launches, with 19 on the cusp ofapproval in 2025. This includes five label expansions of existing products, such as Karyopharm Therapeutics’ expanding multiple myelomatherapy Xpovio to treat endometrial cancer; and four products that belong to a new drug class, including the first-in-classmenin inhibitor revumenib being developed by Syndax Pharmaceuticals for acute myeloid leukemia. Molecule type of key potential drug launches in 2025 Close to half of next year’s total potential drug launches are small-molecule drugs, while monoclonal antibodiesrepresent roughly one-fifth of the total. The “other” category includes Gritstone bio’s GRANITE, a personalized neoantigen-based vaccine for colorectal cancer;and Capricor’s deramiocel, an allogenic cardiosphere-derived cell therapy for Duchenne muscular dystrophy. About Biomedtracker Biomedtracker is your essential platform for real-time insights intocommercial, clinical, and regulatory activities. It offers acomprehensive view of the drug development landscape, providingup-to-the-minute tracking of key events, catalysts, and deals. FIND OUT MORE Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company. Pharma Intelligence UK Limited is a company registered in Englandand Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ